<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297270</url>
  </required_header>
  <id_info>
    <org_study_id>1220.47</org_study_id>
    <secondary_id>2010-021716-42</secondary_id>
    <nct_id>NCT01297270</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)</brief_title>
  <official_title>A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the efficacy and safety of two different treatment
      regimens with BI 201335, both in combination with PegIFN/RBV) as compared to standard of care
      (SOC) with PegIFN/RBV alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>Percentage of participants with sustained virologic response 12 weeks post treatment (SVR12) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level&lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response 24 Weeks Post-treatment (SVR24)</measure>
    <time_frame>24 weeks post treatment, up to 72 weeks</time_frame>
    <description>Percentage of participants with sustained virologic response 24 weeks post-treatment (SVR24), defined as plasma HCV RNA level &lt; 25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.
Hepatitis C virus Ribonucleic acid (HCV RNA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Success (ETS)</measure>
    <time_frame>Week 4 and week 8</time_frame>
    <description>Percentage of participants with early treatment success (ETS), defined as a plasma HCV RNA level &lt;25 IU/mL (detected or undetected) at week 4 and HCV RNA &lt;25 IU/mL (undetected) at week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range at end of treatment (EOT) when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range at end of treatment (EOT) when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range 12 weeks post-treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range 12 weeks post-treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range 12 weeks post-treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range 12 weeks post-treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">658</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PegIFN/RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 201335 for 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 201 335 QD dosing in combination with IFN/RBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI201335 for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 201335 QD doing in combination with PEFG IFN/RBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI201335</intervention_name>
    <description>QD BI 201335</description>
    <arm_group_label>BI201335 for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN/RBV</intervention_name>
    <arm_group_label>PegIFN/RBV</arm_group_label>
    <arm_group_label>BI 201335 for 24 weeks</arm_group_label>
    <arm_group_label>BI201335 for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI201335</intervention_name>
    <description>QD (once daily) BI 201335</description>
    <arm_group_label>BI 201335 for 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Chronic hepatitis C infection, diagnosed by positive anti-HCV antibodies and detected
             HCV RNA at screening in addition to:

               1. positive anti-HCV antibodies or detected HCV RNA at least 6 months prior to
                  screening; or,

               2. liver biopsy consistent with chronic HCV infection.

          2. HCV genotype 1 infection confirmed by genotypic testing at screening.

          3. Therapy-naïve to interferon, pegylated interferon, ribavirin or any antiviral /
             immunomodulatory drug for acute or chronic HCV infection.

          4. HCV RNA = 1,000 IU/mL at screening

          5. Documentation of a liver biopsy within 3 years or fibroscan within 6 months of the
             screening visit.

             Note: If cirrhosis has been previously demonstrated on a biopsy, then biopsies
             obtained more than 3 years before enrolment need not be repeated. Biopsies can be
             waived for patients who would be placed at risk from the procedure. Inability to do a
             liver biopsy should not exclude patients from a trial.

          6. Age 18 to 70 years

          7. Female patients:

             (c) with documented hysterectomy, (d) who have had both ovaries removed, (e) with
             documented tubal ligation, (f) who are post-menopausal with last menstrual period at
             least 12 months prior to screening, or (g) of childbearing potential with a negative
             serum pregnancy test at screening and Day 1, that, if sexually active, agree to use
             one of the appropriate medically accepted methods of birth control from the date of
             screening until 7 months after the last dose of ribavirin in addition to the
             consistent and correct use of a condom. Patients must agree not to breast-feed at any
             time from the date of screening until 7 months after the last dose of ribavirin.

             Medically accepted methods of contraception for females in this trial are ethinyl
             estradiol-containing contraceptives, diaphragm with spermicide substance and
             intra-uterine device.

             Male patients:

               1. who are documented to be sterile, or

               2. who are without pregnant female partner(s) and consistently and correctly use a
                  condom while their female partner(s) (if of child-bearing potential) use one of
                  the appropriate medically accepted methods of birth control from the date of
                  screening until 7 months after the last dose of ribavirin. It is in the
                  responsibility of the male patient to ensure that his partner(s) is not pregnant
                  prior to screening into the study or becomes pregnant during the treatment and
                  the observation phase.

          8. Signed informed consent form prior to trial participation

        Exclusion criteria:

          1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at
             screening.

          2. Evidence of acute or chronic liver disease due to causes other than chronic HCV
             infection.

          3. HIV co-infection.

          4. Hepatitis B virus (HBV) infection based on presence of HBs-Ag.

          5. Active malignancy, or history of malignancy within the last 5 years prior to screening
             (with an exception of appropriately treated basal cell carcinoma of the skin or in
             situ carcinoma of the uterine cervix)

          6. Active or, history of alcohol or illicit drug abuse other than cannabis within the
             past 12 months

          7. A condition that is defined as one which in the opinion of investigator may put the
             patient at risk because of participation in this study, may influence the results of
             this study, or limit the patient¿s ability to participate in this study.

          8. Usage of any investigational drugs within 28 days prior to screening, or planned usage
             of an investigational drug during the course of this study.

          9. Received concomitant systemic antiviral, hematopoietic growth factor, or
             immunomodulatory treatment within 28 days prior to screening. Patients being treated
             with oral antivirals such as acyclovir, famciclovir or valacyclovir for recurrent
             herpes simplex infection; or with oseltamivir or zanamivir for influenza A infection,
             may be screened.

         10. Received silymarin (milk thistle), glycyrrhizin, or Sho-saiko-to (SST) within 28 days
             prior to screening and throughout the treatment phase.

         11. Known hypersensitivity to any ingredient of the study drugs.

         12. Alpha fetoprotein value &gt;100 ng/mL at screening; if &gt;20 ng/mL and =100 ng/mL, patients
             may be included if there is no evidence of liver cancer in an appropriate imaging
             study (e.g., ultrasound, CT scan, or MRI) within last 6 months prior to randomization
             (Visit 2).

         13. Decompensated liver disease, or history of decompensated liver disease, as defined by
             the presence of: hepatic encephalopathy, ascites, or esophageal variceal bleeding
             and/or laboratory results of any of the following:

               1. International normalized ratio (INR) of =1.7

               2. Serum Albumin =3.5 g/dL

               3. Serum total bilirubin =2.0 mg/dL (except when the increase is predominately due
                  to unconjugated bilirubin and related to Gilberts syndrome).

         14. Pre-existing psychiatric condition that could interfere with the subject¿s
             participation in and completion of the study including but not limited to prior
             suicidal attempt, schizophrenia, major depression syndrome, severe anxiety, severe
             personality disorder, a period of disability or impairment due to a psychiatric
             disease within the past 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.47.0004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0099 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaiparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulepo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0097 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0090 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0098 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.1014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.0034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.47.8805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>August 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2015</results_first_posted>
  <disposition_first_submitted>May 6, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 21, 2014</disposition_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Faldaprevir 120mg and PegIFN/RBV</title>
          <description>Faldaprevir (BI 201335) 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="P2">
          <title>Faldaprevir 240mg and PegIFN/RBV</title>
          <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="P3">
          <title>Placebo and PegIFN/RBV</title>
          <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="264"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose.</population>
      <group_list>
        <group group_id="B1">
          <title>Faldaprevir 120mg and PegIFN/RBV</title>
          <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="B2">
          <title>Faldaprevir 240mg and PegIFN/RBV</title>
          <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="B3">
          <title>Placebo and PegIFN/RBV</title>
          <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="262"/>
            <count group_id="B2" value="263"/>
            <count group_id="B3" value="132"/>
            <count group_id="B4" value="657"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="10.05"/>
                    <measurement group_id="B2" value="50.4" spread="9.40"/>
                    <measurement group_id="B3" value="50.2" spread="8.78"/>
                    <measurement group_id="B4" value="50.3" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</title>
        <description>Percentage of participants with sustained virologic response 12 weeks post treatment (SVR12) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level&lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</title>
          <description>Percentage of participants with sustained virologic response 12 weeks post treatment (SVR12) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level&lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="62.3" upper_limit="73.6"/>
                    <measurement group_id="O2" value="64.3" lower_limit="58.5" upper_limit="70.1"/>
                    <measurement group_id="O3" value="47.0" lower_limit="38.5" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
            <estimate_desc>Estimate adjusted for genotype and race using Koch's method, with continuity correction</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.3</ci_lower_limit>
            <ci_upper_limit>27.4</ci_upper_limit>
            <estimate_desc>Estimate adjusted for genotype and race using Koch's method, with continuity correction</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response 24 Weeks Post-treatment (SVR24)</title>
        <description>Percentage of participants with sustained virologic response 24 weeks post-treatment (SVR24), defined as plasma HCV RNA level &lt; 25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.
Hepatitis C virus Ribonucleic acid (HCV RNA)</description>
        <time_frame>24 weeks post treatment, up to 72 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication and had SVR data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response 24 Weeks Post-treatment (SVR24)</title>
          <description>Percentage of participants with sustained virologic response 24 weeks post-treatment (SVR24), defined as plasma HCV RNA level &lt; 25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.
Hepatitis C virus Ribonucleic acid (HCV RNA)</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication and had SVR data at week 24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="61.5" upper_limit="72.9"/>
                    <measurement group_id="O2" value="62.7" lower_limit="56.9" upper_limit="68.6"/>
                    <measurement group_id="O3" value="46.2" lower_limit="37.7" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
            <estimate_desc>Estimate adjusted for genotype and race using Koch's method, with continuity correction</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>26.7</ci_upper_limit>
            <estimate_desc>Estimate adjusted for genotype and race using Koch's method, with continuity correction</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Treatment Success (ETS)</title>
        <description>Percentage of participants with early treatment success (ETS), defined as a plasma HCV RNA level &lt;25 IU/mL (detected or undetected) at week 4 and HCV RNA &lt;25 IU/mL (undetected) at week 8.</description>
        <time_frame>Week 4 and week 8</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Treatment Success (ETS)</title>
          <description>Percentage of participants with early treatment success (ETS), defined as a plasma HCV RNA level &lt;25 IU/mL (detected or undetected) at week 4 and HCV RNA &lt;25 IU/mL (undetected) at week 8.</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="79.1"/>
                    <measurement group_id="O3" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range at end of treatment (EOT) when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range at end of treatment (EOT) when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL normal to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL elevated to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, No ALT data available at EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range at end of treatment (EOT) when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range at end of treatment (EOT) when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL normal to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL elevated to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, No ALT data available at EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=YES</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range 12 weeks post-treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=YES</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range 12 weeks post-treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, No ALT data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=NO</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range 12 weeks post-treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=NO</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range 12 weeks post-treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, No ALT data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL normal to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL elevated to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, No AST data available at EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL normal to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL elevated to EOT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, No AST data available at EoT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=YES</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range 12 weeks post-treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=YES</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range 12 weeks post-treatment when patients have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = Yes, No AST data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=NO</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range 12 weeks post-treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg and PegIFN/RBV</title>
            <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 240mg and PegIFN/RBV</title>
            <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Placebo and PegIFN/RBV</title>
            <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=NO</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range 12 weeks post-treatment when patients do not have sustained virological response 12 weeks post-treatment. BL = Baseline</description>
          <population>Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12 = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12 = No, No AST data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 weeks after treatment discontinuation (Up to 48 weeks treatment)</time_frame>
      <desc>Adverse events (AEs) that pre-existed prior to randomization but worsened during treatment were also considered treatment emergent. All patients who received at least 1 dose of study drug after randomization [safety set (SAF)] were included in the presentation of AE data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Faldaprevir 120mg and PegIFN/RBV</title>
          <description>Faldaprevir 120 mg once daily (oral), for 24 weeks, with Pegylated interferon α-2a (PegIFN/RBV), subcutaneous injection/oral. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="E2">
          <title>Faldaprevir 240mg and PegIFN/RBV</title>
          <description>Faldaprevir 240 mg once daily (oral), for 12 weeks, with PegIFN/RBV (subcutaneous injection/oral). Followed by an additional 12 weeks of placebo plus PegIFN/RBV. At week 24, if the patients did not achieve early treatment success (ETS) the patient received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="E3">
          <title>Placebo and PegIFN/RBV</title>
          <description>Placebo (oral) once daily combined with PegIFN/RBV (subcutaneous injection) for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV (oral) alone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Infective chondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="255" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

